Psychedelics Go Mainstream: Novel Mental Health Treatments | SALT iConnections NY

An all-star panel of industry leaders sat down to discuss the state of psychedelics as a game-changing mental health treatment breakthrough and timeline for mainstream adoption. They explained the use cases between MDMA and psilocybin and the FDA-approval process for both. Then the group talked about the next steps going to market and integrating into insurance, training therapists to use in treatment and finally the investment opportunity for allocators interested in the space.
SPEAKERS:
- Rick Doblin, PhD | Founder & President, Multidisciplinary Association for Psychedelic Studies (MAPS)
- Kabir Nath | Chief Executive Officer, Compass Pathways
- Elliot Cohen | Co-Founder, PillPack
MODERATOR:
- AJ Scaramucci | Co-Chairman & President, SALT
SALT iConnections New York returned to Manhattan's west side for two days of thoughtful panel discussions with leading figures across finance, technology and public policy. Through the iConnections platform, the event also brings together over 2,000 asset allocators, asset managers and entrepreneurs for curated capital introductions.
The event takes place May 20-21, 2024 at the The Glasshouse in New York City. Recorded May 21.
SALT is a global thought leadership and networking forum encompassing finance, technology, and public policy.
To learn more, visit www.salt.org/events/2024-new-...
𝐅𝐨𝐥𝐥𝐨𝐰 𝐒𝐀𝐋𝐓 𝐨𝐧 𝐬𝐨𝐜𝐢𝐚𝐥 𝐦𝐞𝐝𝐢𝐚:
Twitter: / saltconference
Instagram: / salt
LinkedIn: / salt-conference
Chapters:
0:00 - Intro & backgrounds
8:20 - FDA approvals for MDMA
13:05 - Psilocybin & Big Pharma
16:03 - MDMA vs. psilocybin
23:23 - Going to market & insurance
27:48 - Training therapists
29:50 - Investment proposition
#SALTiConnectionsNY